CN1123573C - 用作磷酸二酯酶抑制剂的2－苯基取代的咪唑并三嗪酮 - Google Patents

用作磷酸二酯酶抑制剂的2－苯基取代的咪唑并三嗪酮 Download PDF

Info

Publication number
CN1123573C
CN1123573C CN98811092A CN98811092A CN1123573C CN 1123573 C CN1123573 C CN 1123573C CN 98811092 A CN98811092 A CN 98811092A CN 98811092 A CN98811092 A CN 98811092A CN 1123573 C CN1123573 C CN 1123573C
Authority
CN
China
Prior art keywords
triazin
propyl
methyl
carbon atoms
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN98811092A
Other languages
English (en)
Chinese (zh)
Other versions
CN1278822A (zh
Inventor
U·尼维纳
M·埃斯-萨耶德
H·哈宁
T·申克
K·-H·施莱默
J·克尔德尼希
E·比肖夫
E·佩尔兹波恩
K·德姆波夫斯基
P·塞尔诺
M·诺瓦科夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Bayer Intellectual Property GmbH
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1123573(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19750085A external-priority patent/DE19750085A1/de
Priority claimed from DE1998112462 external-priority patent/DE19812462A1/de
Priority claimed from DE1998140289 external-priority patent/DE19840289A1/de
Application filed by Bayer AG filed Critical Bayer AG
Publication of CN1278822A publication Critical patent/CN1278822A/zh
Application granted granted Critical
Publication of CN1123573C publication Critical patent/CN1123573C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN98811092A 1997-11-12 1998-10-31 用作磷酸二酯酶抑制剂的2－苯基取代的咪唑并三嗪酮 Expired - Lifetime CN1123573C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE19750085A DE19750085A1 (de) 1997-11-12 1997-11-12 2-Phenyl-substituierte Imidazotriazinone
DE19750085.4 1997-11-12
DE19812462.7 1998-03-23
DE1998112462 DE19812462A1 (de) 1998-03-23 1998-03-23 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid
DE19840289.9 1998-09-04
DE1998140289 DE19840289A1 (de) 1998-09-04 1998-09-04 2-Phenyl-substituierte Imidazotriazinone

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB031199402A Division CN100430396C (zh) 1997-11-12 1998-10-31 用作磷酸二酯酶抑制剂的2-苯基取代的咪唑并三嗪酮

Publications (2)

Publication Number Publication Date
CN1278822A CN1278822A (zh) 2001-01-03
CN1123573C true CN1123573C (zh) 2003-10-08

Family

ID=27217917

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB031199402A Expired - Lifetime CN100430396C (zh) 1997-11-12 1998-10-31 用作磷酸二酯酶抑制剂的2-苯基取代的咪唑并三嗪酮
CN98811092A Expired - Lifetime CN1123573C (zh) 1997-11-12 1998-10-31 用作磷酸二酯酶抑制剂的2－苯基取代的咪唑并三嗪酮

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNB031199402A Expired - Lifetime CN100430396C (zh) 1997-11-12 1998-10-31 用作磷酸二酯酶抑制剂的2-苯基取代的咪唑并三嗪酮

Country Status (43)

Country Link
US (9) US6362178B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP1174431B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP3356428B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR100548120B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN100430396C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR013759A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE213246T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU738675B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG65257B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (2) BR9816155B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA2395558C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH693954A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO4980861A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CU (1) CU23063A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1112949T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ301911B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (3) DE19881732C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (3) DK1049695T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE04781B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES2386420T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI113772B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2346877B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HN (1) HN1998000175A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (2) HRP20000292B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (3) HU230154B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID25871A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL135462A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN188419B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU90561B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY138535A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (2) NO314940B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ504436A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE131799A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL194801B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT1049695E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE522809C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI1174431T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK287161B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR200001338T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (2) TW513431B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA46166C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (2) UY25246A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1999024433A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
IL135462A0 (en) * 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
DE19827640A1 (de) 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
IL139457A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
WO2001047929A1 (de) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Triazolotriazinone und ihre verwendung
CN1434825A (zh) 1999-12-24 2003-08-06 拜尔公司 咪唑并[1,3,5]三嗪酮及其应用
AU2365001A (en) 1999-12-24 2001-07-09 Bayer Aktiengesellschaft Isoxazolo pyrimidinones and the use thereof
DE10010067A1 (de) 2000-03-02 2001-09-06 Bayer Ag Neue Imidazotriazinone und ihre Verwendung
US20020006926A1 (en) 2000-04-19 2002-01-17 Roylance H. H. Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
AR037080A1 (es) * 2000-09-29 2004-10-20 Glaxo Group Ltd Compuestos utiles en el tratamiento de enfermedades inflamatorias,composiciones que los contienen, su uso en terapia, metodos de tratamiento, procesos de preparacion e intermediarios
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
DE10063108A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von Sulfonamid-substituierten Imidazotriazinonen
DE10063106A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von 2-(2-Ethoxyphenyl)-substituierten Imidazotriazinonen
DE10064105A1 (de) * 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
AU2002226633A1 (en) 2001-02-02 2002-08-12 Pfizer Limited Treatment of diabetes mellitus using vardenafil
DE10107639A1 (de) * 2001-02-15 2002-08-22 Bayer Ag 2-Alkoxyphenyl-substituierte Imidazotriazinone
DE10108752A1 (de) * 2001-02-23 2002-09-05 Bayer Ag Neue Substituierte Imidazotriazinone
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
PL363679A1 (en) * 2001-05-09 2004-11-29 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
GB0113344D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
CN1781920A (zh) 2001-08-28 2006-06-07 先灵公司 多环鸟嘌呤磷酸二酯酶v抑制剂
CA2465893A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
EP1454897B1 (en) * 2001-12-13 2007-10-10 Asubio Pharma Co., Ltd. Pyrazolopyrimidinone derivatives having pde7-inhibitory activity
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
GB0209988D0 (en) * 2002-05-01 2002-06-12 Bayer Ag Novel Heterocycles
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003265239A1 (en) 2002-05-22 2003-12-19 Virginia Commonwealth University Protective effects of pde-5 inhibitors
WO2003099194A2 (en) * 2002-05-23 2003-12-04 Pfizer Limited Pharmaceutical combination of pde5 inhibitors with ace inhibitors
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
NZ539972A (en) 2002-12-13 2008-05-30 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
ATE432936T1 (de) 2003-04-01 2009-06-15 Smithkline Beecham Corp Imidazotriazin verbindungen zur behandlung von krebserkrankungen
JP4015176B2 (ja) 2003-04-29 2007-11-28 ファイザー・インク 高血圧症の治療に有用な５，７−ジアミノピラゾロ４，３−ジピリミジン類
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2004104492A2 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same
NZ544040A (en) 2003-05-22 2009-03-31 Nycomed Gmbh Composition comprising a PDE4 inhibitor and a PDE5 inhibitor
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
JP2006219374A (ja) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
EP1691788A2 (en) * 2003-11-21 2006-08-23 Schering Corporation Phosphodiesterase v inhibitor formulations
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
DE602005011784D1 (de) * 2004-04-07 2009-01-29 Pfizer Pyrazoloä4,3-düpyrimidine
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
JP2008501617A (ja) * 2004-06-11 2008-01-24 アスビオファーマ株式会社 Ｐｄｅ７阻害作用を有するイミダゾトリアジノン誘導体
AU2004322756B2 (en) 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
US20080176844A1 (en) * 2005-02-18 2008-07-24 Stewart Campbell Pharmacokinetically Improved Compounds
CA2598270A1 (en) * 2005-02-18 2006-08-24 Surface Logix, Inc. Methods of making pharmacokinetically improved compounds comprising functional residues or groups and pharmaceutical compositions comprising said compounds
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005016345A1 (de) * 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
BRPI0610498A2 (pt) 2005-04-19 2010-06-22 Nycomed Gmbh uso de roflumilast,composição farmacêutica, produto de combinação e kit para o tratamento de hipertensão pulmonar
MX2007013215A (es) 2005-05-12 2007-12-12 Pfizer Formas cristalinas anhidras de la n-[1-(2-etoxietil)-5-(n-etil-n- metilamino)-7-(4-metilpiridin-2-il-amino)-1h-pirazolo[4,3-d] pirimidina -3-carbonil] metanosulfonamida.
US20060264624A1 (en) * 2005-05-20 2006-11-23 Alexander Heim-Riether Methods for synthesizing imidazotriazinones
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
US20100222365A1 (en) * 2005-08-10 2010-09-02 Pfizer Inc Substituted triazole deriviatives as oxytocin antagonists
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
RU2435588C2 (ru) 2005-09-29 2011-12-10 Байер Шеринг Фарма Акциенгезельшафт Ингибиторы фдэ и их комбинации для лечения урологических расстройств
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
TW200732295A (en) * 2006-02-17 2007-09-01 Wyeth Corp Selective N-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
EP1984321A1 (en) * 2006-02-17 2008-10-29 Wyeth Methods for preparing sulfonamide substituted alcohols and intermediates thereof
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7977478B2 (en) * 2006-03-13 2011-07-12 Dr. Reddy's Laboratories Limited Polymorphic forms of vardenafil
HUE030920T2 (en) * 2006-03-17 2017-06-28 Univ Johns Hopkins N-hydroxylsulfonamide derivatives as novel physiologically useful nitroxyl donors
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007249435A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
SI2032521T1 (sl) 2006-06-27 2010-02-26 Sandoz Ag Nov postopek za pripravo soli
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
BRPI0716571A2 (pt) 2006-08-24 2013-11-05 Surface Logix Inc Compostos farmacocineticamente otimizados
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
DE102006043443A1 (de) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
PL2101777T3 (pl) 2006-12-12 2015-10-30 Gilead Sciences Inc Kompozycja do leczenia nadciśnienia płucnego
CN101674728A (zh) 2007-02-12 2010-03-17 Dmi生物科学公司 降低曲马多的副作用
WO2008100886A1 (en) * 2007-02-12 2008-08-21 Auspex Pharmaceuticals, Inc. Preparation and use of deuterated udenafil analogues as highly selective pde5 modulators for the treatment of erectile dysfunction
ES2384481T3 (es) 2007-02-12 2012-07-05 Dmi Biosciences, Inc. Tratamiento de la eyaculación precoz y la disfunción eréctil co-morbidas
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
DE102007027067A1 (de) 2007-06-12 2008-12-18 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Vardenafil Hydrochlorid Trihydrat
US20100184769A1 (en) * 2007-06-13 2010-07-22 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
CN101965348B (zh) * 2007-09-06 2013-11-13 上海特化医药科技有限公司 伐地那非的制备方法及其中间体
US8410098B2 (en) 2007-12-28 2013-04-02 Topharman Shanghai Co., Ltd. N-{1-[3-(2-ethoxy-5-(4-ethylpiperazinyl)sulfonylphenyl)-4,5-dihydro-5-OXO-1,2,4-triazin-6-yl]ethyl}butyramide, the preparation method and use thereof
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009020888A1 (de) 2009-05-12 2010-11-18 Ratiopharm Gmbh Schmelztablette, enthaltend ein Vardenafil-Salz
CA2770471A1 (en) 2009-08-07 2011-02-10 Ranbaxy Laboratories Limited Processes for the preparation of vardenafil
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
PT3415515T (pt) 2009-11-27 2020-03-10 Adverio Pharma Gmbh Processo para a produção de carbamato de metil-{4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il} metilo
US8829049B2 (en) 2009-12-21 2014-09-09 Acef S.A. Medicinal composition intended for the treatment of erectile dysfunction in mammals and use of the composition
PL390079A1 (pl) * 2009-12-30 2011-07-04 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób otrzymywania wardenafilu i jego izolacji jako soli z kwasem cytrynowym oraz krystaliczna postać tej soli
KR101377178B1 (ko) 2010-04-05 2014-03-26 에스케이케미칼주식회사 Ｐｄｅ5 억제제를 함유하는 피부 주름 개선용 조성물
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN102372730B (zh) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 桥环取代的磷酸二酯酶抑制剂
CN102382129B (zh) * 2010-08-19 2014-02-26 山东轩竹医药科技有限公司 螺环取代的磷酸二酯酶抑制剂
MX2013003093A (es) 2010-09-20 2013-10-28 Envivo Pharmaceuticals Inc Compuestos de imidazotriazinona.
AU2011305462B2 (en) 2010-09-23 2015-11-26 Abbvie Bahamas Ltd. Monohydrate of an azaadamantane derivative
EA201691759A1 (ru) 2010-10-15 2017-05-31 Джилид Сайэнс, Инк. Композиции и способы лечения легочной гипертензии
TWI462739B (zh) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
CA2886885C (en) 2011-10-10 2019-07-16 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
CZ303877B6 (cs) * 2011-11-24 2013-06-05 Zentiva, K.S. Zpusob prípravy a izolace solí vardenafilu s kyselinami
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
EP3178820B1 (en) 2012-01-26 2017-12-20 H. Lundbeck A/S Pde9- inhibitors with imidazo triazinone backbone
IN2014MN01706A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-02-28 2015-05-29 Seoul Pharma Co Ltd
HK1206726A1 (en) 2012-03-19 2016-01-15 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
CN103374002B (zh) * 2012-04-19 2015-07-15 山东轩竹医药科技有限公司 磷酸二酯酶-5抑制剂
CZ307091B6 (cs) 2012-09-14 2018-01-10 Zentiva, K.S. Stabilní farmaceutický přípravek obsahující Vardenafil hydrochlorid
ES2903151T3 (es) 2012-12-04 2022-03-31 Aribio Inc Composición que comprende inhibidor de fosfodiesterasa tipo 5 para inhibir la apoptosis de células nerviosas
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
BR112015019571A2 (pt) 2013-02-21 2017-07-18 Adverio Pharma Gmbh formas de {4,6-diamino-2-[1-(2-fluorobenzil)-1h-pirazolo[3,4-b]piridino-3-il]pirimidino-5-il}metilcarbamato de metila
CN104109164B (zh) * 2013-04-18 2016-05-25 广州朗圣药业有限公司 一种适合工业化的高纯度盐酸伐地那非三水合物的制备方法
EP3022205B1 (en) 2013-07-17 2020-02-05 The Trustees of Columbia University in the City of New York Novel phosphodiesterase inhibitors and uses thereof
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
PL223869B1 (pl) 2013-12-16 2016-11-30 Starogardzkie Zakłady Farm Polpharma Spółka Akcyjna Sposób otrzymywania wardenafilu i jego soli
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
US10513524B2 (en) 2015-07-07 2019-12-24 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
MX380708B (es) * 2015-11-16 2025-03-12 Topadur Pharma Ag Derivados de 2-fenil-3,4-dihidropirrolo[2,1-f][1,2,4]triazinona como inhibidores de fosfodiesterasa y sus usos.
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
BR112019012251A2 (pt) 2016-12-14 2019-11-05 Respira Therapeutics Inc métodos e composições para tratamento de hipertensão pulmonar e outros distúrbios pulmonares
JP7182568B2 (ja) 2017-05-22 2022-12-02 トパドゥール ファーマ アーゲー 新規二重作用モード可溶性グアニル酸シクラーゼ活性化因子およびホスホジエステラーゼ阻害剤ならびにその使用
CN107445964A (zh) * 2017-07-29 2017-12-08 合肥创新医药技术有限公司 一种盐酸伐地那非杂质的合成方法
KR20200106164A (ko) 2017-12-20 2020-09-11 클라리아 파마 홀딩 에이비 바르데나필을 포함하는 필름 제형, 그 제조 방법 및 용도
US12214118B2 (en) 2018-02-02 2025-02-04 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
BR112020024019A2 (pt) 2018-05-25 2021-02-23 Imara Inc. monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona
US11348670B2 (en) 2018-06-14 2022-05-31 Astrazeneca Uk Limited Methods for treating erectile dysfunction with a cGMP-specific phosphodiesterase 5 inhibitor pharmaceutical composition
CA3103716A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
KR102831968B1 (ko) 2018-08-31 2025-07-08 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
KR20210096626A (ko) * 2018-11-28 2021-08-05 토파두르 파마 아게 가용성 구아닐레이트 사이클라제 활성제 및 포스포디에스테라제 억제제의 신규한 이중 작용 방식 및 이의 용도
KR102820317B1 (ko) 2019-03-13 2025-06-16 오츠카 세이야쿠 가부시키가이샤 2급 아민을 함유하는 화합물의 아민 부분에 중수소 저급 알킬을 도입하는 방법
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
PE20240248A1 (es) * 2020-12-11 2024-02-19 Ildong Pharmaceutical Co Ltd Nuevos compuestos como inhibidor dual del receptor de androgenos y de la fosfodiesterasa
CN114085225A (zh) * 2021-06-04 2022-02-25 广东西捷药业有限公司 一种伐地那非类似物及其合成方法和应用
MX2024003995A (es) 2021-09-29 2024-07-01 Topadur Pharma Ag Composiciones topicas de derivados de 2-fenil-3,4-dihidropirrolo[2 ,l-f][1,2,4]triazinona y usos de estos.
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
AU2023227111A1 (en) 2022-03-02 2024-07-25 Topadur Pharma Ag Topical compositions and uses therof
WO2024173675A1 (en) 2023-02-16 2024-08-22 University Of Rochester Improving glymphatic-lymphatic efflux

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941785A (en) * 1973-01-04 1976-03-02 Allen & Hanburys Limited Imidazo [5,1-f]-as-triazines
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5482941A (en) * 1991-12-11 1996-01-09 Pfizer Inc. Quinazolinone antianginal agents
CN1124926A (zh) * 1993-06-09 1996-06-19 辉瑞研究及发展公司 用于治疗阳痿的吡唑并嘧啶酮类
US5591742A (en) * 1992-08-28 1997-01-07 Pfizer Inc. Pyridopyrimidinone antianginal agents

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US26565A (en) * 1859-12-27 Improved register for railroad-cars
DE812845C (de) 1944-12-07 1951-09-06 Georges Lissac Brille
US2705715A (en) 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (de) 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1051734A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1963-01-16
GB1042471A (en) 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
US3169129A (en) 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) 1966-03-02 1969-04-29 Table iii
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
BE791025A (fr) 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
US4052390A (en) 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
GB1584461A (en) 1977-03-25 1981-02-11 Allen & Hanburys Ltd Imidazotriazines imidazotriazinones and pharmaceutical compositions containing them
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
US4287673A (en) * 1980-01-11 1981-09-08 Sunbeam Corporation Hair dryer diffuser
DE3166627D1 (en) 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
US4431440A (en) 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS60246396A (ja) 1984-05-22 1985-12-06 Sankyo Co Ltd 酵素阻害物質ジヒドロデスオキシグリゼオ−ル酸及びその塩類
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
ES2058527T3 (es) 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
ATE121619T1 (de) * 1990-04-11 1995-05-15 Upjohn Co Verfahren zum geschmacksabdecken von ibuprofen.
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9119704D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) * 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5614627A (en) 1993-09-10 1997-03-25 Eisai Co., Ltd. Quinazoline compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5374053A (en) * 1994-01-21 1994-12-20 Heidelberger Druckmaschinen Ag Device for changing the transport position of products
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
IL135462A0 (en) 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
CN1434825A (zh) * 1999-12-24 2003-08-06 拜尔公司 咪唑并[1,3,5]三嗪酮及其应用
PL363679A1 (en) 2001-05-09 2004-11-29 Bayer Healthcare Ag Novel use of 2-phenyl-substituted imidazotriazinones
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941785A (en) * 1973-01-04 1976-03-02 Allen & Hanburys Limited Imidazo [5,1-f]-as-triazines
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5482941A (en) * 1991-12-11 1996-01-09 Pfizer Inc. Quinazolinone antianginal agents
US5591742A (en) * 1992-08-28 1997-01-07 Pfizer Inc. Pyridopyrimidinone antianginal agents
CN1124926A (zh) * 1993-06-09 1996-06-19 辉瑞研究及发展公司 用于治疗阳痿的吡唑并嘧啶酮类

Also Published As

Publication number Publication date
US20040067945A1 (en) 2004-04-08
US20060189615A1 (en) 2006-08-24
IL135462A (en) 2006-04-10
ES2194567A1 (es) 2003-11-16
PT1049695E (pt) 2002-07-31
IL135462A0 (en) 2001-05-20
HU227841B1 (en) 2012-05-02
SI1049695T1 (en) 2002-06-30
HRP20020585A2 (en) 2005-10-31
US7314871B2 (en) 2008-01-01
KR100548120B1 (ko) 2006-02-02
PT1174431E (pt) 2012-07-24
SE522809C2 (sv) 2004-03-09
ES2194567B1 (es) 2005-03-01
UY25671A1 (es) 2000-03-31
US7122540B2 (en) 2006-10-17
SK7092000A3 (en) 2001-03-12
CA2395558C (en) 2007-07-17
BG104406A (en) 2001-08-31
CY1112949T1 (el) 2016-04-13
WO1999024433A1 (de) 1999-05-20
HK1031730A1 (en) 2001-06-22
NO20021714D0 (no) 2002-04-11
EP1174431A3 (de) 2002-01-30
GB0010974D0 (en) 2000-06-28
TW513431B (en) 2002-12-11
CN1508137A (zh) 2004-06-30
HUP0100394A2 (hu) 2001-09-28
US6362178B1 (en) 2002-03-26
US20110009367A1 (en) 2011-01-13
US20080113972A1 (en) 2008-05-15
EP1174431A2 (de) 2002-01-23
ES2172945T3 (es) 2002-10-01
NO20002444D0 (no) 2000-05-11
CN100430396C (zh) 2008-11-05
FI113772B (fi) 2004-06-15
PL340400A1 (en) 2001-01-29
TR200001338T2 (tr) 2000-08-21
DE19881732C1 (de) 2002-01-31
EE04781B1 (et) 2007-02-15
BG65257B1 (bg) 2007-10-31
US7696206B2 (en) 2010-04-13
US6890922B2 (en) 2005-05-10
AR035972A2 (es) 2004-07-28
SE0001745L (sv) 2000-05-11
CA2309332A1 (en) 1999-05-20
DK176852B1 (en) 2009-12-14
US20050070541A1 (en) 2005-03-31
EE200000291A (et) 2001-06-15
SK287161B6 (sk) 2010-02-08
HU230154B1 (hu) 2015-09-28
DE59803108D1 (de) 2002-03-21
CU23063A3 (es) 2005-07-19
JP3356428B2 (ja) 2002-12-16
BR9812785A (pt) 2000-10-10
PE131799A1 (es) 1999-12-30
PL201336B1 (pl) 2009-03-31
KR20040014591A (ko) 2004-02-14
NZ504436A (en) 2001-08-31
AU738675B2 (en) 2001-09-20
DE19881732D2 (de) 2000-08-24
UA46166C2 (uk) 2002-05-15
DK200000766A (da) 2000-05-09
ES2386420T3 (es) 2012-08-20
IN188419B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2002-09-21
AU1558799A (en) 1999-05-31
EP2295436A1 (de) 2011-03-16
JP2002348290A (ja) 2002-12-04
EP1174431B1 (de) 2012-05-30
CN1278822A (zh) 2001-01-03
JP4388729B2 (ja) 2009-12-24
KR100430355B1 (ko) 2004-05-04
SE0001745D0 (sv) 2000-05-11
US20130059844A1 (en) 2013-03-07
GB2346877A (en) 2000-08-23
NO20002444L (no) 2000-05-11
JP2001522851A (ja) 2001-11-20
BR9816155B1 (pt) 2010-07-27
CZ301911B6 (cs) 2010-07-28
MY138535A (en) 2009-06-30
TWI229081B (en) 2005-03-11
NO20021714L (no) 2000-05-11
CH693954A5 (de) 2004-05-14
CA2309332C (en) 2002-12-03
HUP0100394A3 (en) 2002-05-28
HRP20020585B1 (hr) 2013-02-28
NO314940B1 (no) 2003-06-16
GB2346877B (en) 2001-12-05
LU90561B1 (de) 2000-12-01
PL194801B1 (pl) 2007-07-31
DK1174431T3 (da) 2012-08-20
ID25871A (id) 2000-11-09
IL163475A (en) 2015-11-30
AR013759A1 (es) 2001-01-10
ATE213246T1 (de) 2002-02-15
UY25246A1 (es) 2001-08-27
US20100016323A1 (en) 2010-01-21
HU228196B1 (en) 2013-01-28
CA2395558A1 (en) 1999-05-20
KR20010031944A (ko) 2001-04-16
HRP20000292B1 (hr) 2008-09-30
HRP20000292A2 (en) 2001-04-30
HK1067124A1 (zh) 2005-04-01
EP1049695B1 (de) 2002-02-13
CZ20001759A3 (cs) 2000-10-11
HN1998000175A (es) 1999-01-08
SI1174431T1 (sl) 2012-09-28
DK1049695T3 (da) 2002-05-13
US6566360B1 (en) 2003-05-20
EP1049695A1 (de) 2000-11-08
CO4980861A1 (es) 2000-11-27
FI20001086L (fi) 2000-05-09
US7704999B2 (en) 2010-04-27

Similar Documents

Publication Publication Date Title
CN1123573C (zh) 用作磷酸二酯酶抑制剂的2－苯基取代的咪唑并三嗪酮
US8765754B2 (en) Pyrrolotriazine compounds
AU780052B2 (en) Pyrazolopyrimidines as therapeutic agents
KR101994381B1 (ko) 키나아제 억제제
TWI436769B (zh) 類Ｐｏｌｏ激酶抑制劑
CN100341876C (zh) 螺环取代的吡咯并嘧啶化合物
US20020156081A1 (en) Pyrazolopyrimidines as therapeutic agents
CN1555374A (zh) 新的吡啶取代的吡唑并吡啶衍生物
US20030195210A1 (en) Novel imidazo[1,3,5]triazinones and the use thereof
OA13289A (en) 5,7-diaminopyrazolo [4,3-d] pyrimidines with PDE-5inhibiting activity.
CN1820009A (zh) 作为激酶抑制剂的吡咯并[3,4－c]吡唑衍生物
CN1041930C (zh) [1,2,4]三唑并[4,3－a]喹喔啉衍生物,其制备及用途
JP2018508494A (ja) 新規シクロプロパベンゾフラニルピリドピラジンジオン
WO2011093365A1 (ja) 含窒素複素環化合物
JP2004521907A (ja) ２−アルコキシフェニル置換されたイミダゾトリアジノン
CN1604904A (zh) 作为丝氨酸蛋白酶抑制剂的膦酸化合物
HK1031730B (en) 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
CN1227230C (zh) Nmda受体配体的前药
RU2260593C2 (ru) 2-фенилзамещенные имидазотриазиноны, способ их получения и фармацевтическая композиция на их основе, обладающая свойствами ингибитора фосфодиэстеразы i,ii и v
US6777416B2 (en) Isoxazolo pyrimidinones and the use thereof
HK1067124B (en) 2-phenyl-substituited imidazotriazinones as phoshodiesterase inhibitors
HK1057559A (en) Novel imidazo(1,3,5) triazinones and the use thereof
HK1020193B (en) Pyridazino [4,5-b] -quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists
HK1020193A1 (en) Pyridazino [4,5-b] -quinoline 5-oxide derivatives, their preparation and their use as glycine antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: BAYER HEALTHCARE AG

Free format text: FORMER OWNER: BAYER AG

Effective date: 20041022

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20041022

Address after: Germany Leverkusen

Patentee after: BAYER HEALTHCARE AG

Address before: Germany Leverkusen

Patentee before: Bayer AG

CI01 Publication of corrected invention patent application

Correction item: 10., the transfer of the patent holder

Correct: Bayer Healthcare AG

False: Bayer Healthcare AG

Number: 48

Page: 628

Volume: 20

ERR Gazette correction

Free format text: CORRECT: 10. PATENTEE TRANSFER; FROM: BAYER HEALTHCARE AG TO: BAYER HEALTHCARE AG

ASS Succession or assignment of patent right

Owner name: BAYER SCHERING PHARMA AG

Free format text: FORMER OWNER: BAYER HEALTHCARE AG

Effective date: 20091204

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20091204

Address after: Berlin

Patentee after: Bayer Schering Pharma AG

Address before: Germany Leverkusen

Patentee before: Bayer Healthcare AG

ASS Succession or assignment of patent right

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

Free format text: FORMER OWNER: BAYER PHARMACEUTICALS AG

Effective date: 20130327

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: BAYER PHARMACEUTICALS AG

Free format text: FORMER NAME: BAYER SCHERING PHARMA AG

CP01 Change in the name or title of a patent holder

Address after: Berlin

Patentee after: BAYER PHARMA AG

Address before: Berlin

Patentee before: Bayer Schering Pharma AG

TR01 Transfer of patent right

Effective date of registration: 20130327

Address after: German Monheim

Patentee after: BAYER INTELLECTUAL PROPERTY GmbH

Address before: Berlin

Patentee before: BAYER PHARMA AG

CX01 Expiry of patent term

Granted publication date: 20031008

CX01 Expiry of patent term